Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
27 Noviembre 2023 - 3:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of November 2023 (Report No.2)
Commission file number: 001-38041
SCISPARC LTD.
(Translation of registrant’s name into English)
20 Raul Wallenberg Street, Tower A,
Tel Aviv 6971916 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
On November 27, 2023, SciSparc
Ltd. (the “Company”) issued a press release titled “SciSparc Announces Positive Results for MitoCareX Bio with its Drug
Discovery Platform.” A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
The press release furnished
as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration
statements on Form F-3 (File No. 333-275305, File No. 333-269839, File No. 333-266047, File No. 333-233417, File No. 333-248670, File
No. 333-255408, and File No. 333-275305) and on Form S-8 (File No. 333-225773) filed with the Securities and Exchange Commission to be
a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
SciSparc Ltd. |
|
|
|
Date: November 27, 2023 |
By: |
/s/ Oz Adler |
|
Name: |
Oz Adler |
|
Title: |
Chief Executive Officer and
Chief Financial Officer |
3
Exhibit 99.1
SciSparc Announces Positive Results for MitoCareX
Bio with its Drug Discovery Platform
MitoCareX Bio has met its second milestone as
part of its joint venture agreement with the Company
TEL AVIV, Israel, Nov. 27, 2023 (GLOBE
NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage
pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system,
today announced that MitoCareX Bio Ltd. (“MitoCare X Bio”), its joint venture with Dr. Alon Silberman, that focuses on
the discovery and development of drugs for cancer treatment, has achieved positive results with the development of its laboratory
capabilities by establishing a variety of small-molecule screening platforms.
With this development, MitoCareX Bio has achieved its second milestone
pursuant to the Founders and Investment Agreement, signed on March 10, 2022 (the “Agreement”).
MitoCareX Bio is a drug discovery company focusing on targeting the
nuclear encoded human mitochondrial carriers – the largest solute transporter family in humans
(Solute Carrier Family 25, SLC25). Consisting of 53 members, transporters of this mitochondrial family are found to be altered
in diverse types of malignancies due to their significant role in the cytosol-mitochondria crosstalk. Pursuant to the Agreement, MitoCareX
Bio completed the experimental testing and validating of its diverse in-vitro small molecule screening systems to enable rapid and reliable
validations of its in-silico (virtual) results. Following the experimental testing and validating of its results, MitoCareX Bio thereby
achieved its second milestone by developing multiple lab screening platforms that screen for and, in turn, isolate potential anti-cancer
drug molecules for pre-clinical studies.
As per the Agreement, reaching the second milestone results triggers
the condition that SciSparc invest an additional $600,000 into the joint venture within 30 days of the date the second milestone was achieved.
Following this investment, the Company will hold 50.1% of the issued and outstanding share capital of MitoCare X Bio.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company
led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies
and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs
based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and
agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling
interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on Amazon Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning
of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For
example, SciSparc is using forward-looking statements when it discusses the furtherance of the joint venture’s clinical development
as facilitated by the small-molecule screening platforms and that the achievement of the second milestone of the Agreement triggers SciSparc’s
additional investment into the joint venture and, in turn, its impending majority stake in MitoCareX Bio. Historical results of scientific
research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical
or even similar conclusions. The forward-looking statements contained or implied in this press release are subject to other risks and
uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with
the SEC on May 1, 2023, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required
by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the
date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
SciSparc (NASDAQ:SPRC)
Gráfica de Acción Histórica
De May 2023 a May 2024